Search Results
Oct 29, 2025, 08:30 ET Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
Biotherapeutics Inc. (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), Eli Lilly and Company (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ)
More news about: NetworkNewsWire
Oct 29, 2025, 08:05 ET Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
SPRING HOUSE, Pa., Oct. 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which
More news about: Johnson & Johnson
Oct 27, 2025, 08:00 ET New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
SPRING HOUSE, Pa., Oct. 27, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced findings from the U.S. dataset from the global ENCOMPASS study evaluating patient and healthcare provider (HCP) perspectives on barriers
More news about: Johnson & Johnson
Oct 27, 2025, 07:30 ET Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
NCT06049017) is a Phase 2b multicenter, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of icotrokinra (JNJ-77242113, JNJ-2113) in patients with moderately to severely active ulcerative colitis who had an inadequate response or intolerance to conventional therapy (e.g.,
More news about: Johnson & Johnson
Oct 27, 2025, 07:30 ET TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
PHOENIX, Oct. 27, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability
More news about: Johnson & Johnson
Oct 24, 2025, 18:32 ET Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
SPRING HOUSE, Pa., Oct. 24, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced findings from the Phase 2 DAHLIAS study published in
More news about: Johnson & Johnson
Oct 24, 2025, 08:00 ET Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
can have an increased negative impact on quality of life.16,18 About Icotrokinra (JNJ-77242113, JNJ-2113) Investigational icotrokinra is the first targeted oral peptide designed to precisely block the IL-23 receptor,19 which
More news about: Johnson & Johnson
Oct 10, 2025, 07:30 ET Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
TITUSVILLE, N.J., Oct. 10, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 17 abstracts featuring new clinical and real-world data will be presented at the annual European College of Neuropsychopharmacology
More news about: Johnson & Johnson
Oct 07, 2025, 08:05 ET Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill
NCT06049017) is a Phase 2b multicenter, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of icotrokinra (JNJ-77242113, JNJ-2113) in patients with moderately to severely active ulcerative colitis who had an inadequate response or intolerance to conventional therapy (e.g.,
More news about: Johnson & Johnson
Oct 07, 2025, 08:05 ET TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis
SPRING HOUSE, Pa., Oct. 7, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new 48-week data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction and maintenance
More news about: Johnson & Johnson
Oct 07, 2025, 08:00 ET Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
first Phase 1 data from its dose escalation study evaluating JNJ-1900 (NBTXR3) in 13 patients with locally advanced esophageal adenocarcinoma, demonstrating an 85% disease control rate and 69% objective response rate
More news about: Equity Insider
Sep 29, 2025, 08:00 ET U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
HORSHAM, Pa., Sept. 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of children six years
More news about: Johnson & Johnson
Sep 19, 2025, 17:28 ET TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
HORSHAM, Pa., Sept. 19, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) induction regimen of TREMFYA® (guselkumab)
More news about: Johnson & Johnson
Sep 17, 2025, 08:00 ET Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
scalp, hands, feet, and genitals, can have an increased negative impact on quality of life.15,16 About Icotrokinra (JNJ-77242113, JNJ-2113) Investigational icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor,17 which
More news about: Johnson & Johnson
Sep 15, 2025, 08:00 ET Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
TITUSVILLE, N.J., Sept. 15, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 21 abstracts featuring new real-world and clinical trial data will be presented at the annual U.S. Psychiatric and Mental Health
More news about: Johnson & Johnson
Sep 12, 2025, 12:35 ET Jack and Jill of America Inc. 舉辦 2025 年「On The Hill」立法峰會：「彰顯我們的聲音」
為能夠彰顯他們的聲音而深感自豪，因為我們堅信，今日的倡議者，正是明日的立法者、法官與總統。他們並非遙遠的未來領袖，而是此時此刻的領導者。」全國主席 Darlene Whittington。 本年度峰會將引領青少年探索個人聲音、磨練領導才能，並自信地肩負起變革者的角色。他們將參與一系列聚焦公民參與及社區影響力的工作坊、論壇和文化活動。焦點項目包括「黑人家庭狀況」論壇、旨在展示青年創業精神的「青少年大亨 JNJ Tank 版」創業比賽，以及「傳承彰顯」主席招待會。峰會的閉幕活動為「Jack and Jill 登上國會山莊」，參與者將與所屬選區的立法者會面，就各項關鍵議題表達主張。 Jack and Jill of America Inc. 即將在華盛頓迎接數百名年輕領袖，「On the Hill
More news about: Jack and Jill of America, Inc.
Sep 11, 2025, 13:00 ET Jack and Jill of America Inc. Presenta la Cumbre Legislativa 2025 On The Hill: Amplificando Nuestras Voces
el impacto comunitario. Los puntos destacados incluyen el foro del Estado de la Familia Negra, la edición Teen Moguls JNJ Tank, un escaparate del emprendimiento juvenil, y la recepción del presidente de Legacy Amplified. La cumbre concluye con el evento Jack
More news about: Jack and Jill of America, Inc.
Sep 11, 2025, 10:07 ET Jack and Jill of America Inc. Hosts 2025 On The Hill Legislative Summit: Amplifying Our Voices
forums, and cultural events focused on civic engagement and community impact. Highlights include the State of the Black Family forum, the Teen Moguls JNJ Tank edition — a showcase of youth entrepreneurship — and the Legacy Amplified president's reception. The summit concludes with Jack
More news about: Jack and Jill of America, Inc.